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Are we letting the genie out of the bottle by diagnosing (classifying) Fibromyalgia
in RA?The study by Wolfe et al. in this issue of PAIN is the ﬁrst obser-
vation of the development of ﬁbromyalgia (FM) in a cohort of
patients [11]. They examined rates and predictors of onset of FM
in patients with rheumatoid arthritis (RA). To deﬁne FM, they used
the new American College of Rheumatology (ACR) 2010 criteria
that allow better tracking of FM status over time compared to
the previous, 1990 ACR criteria [10].
After excluding 9126 patients with FM and those with high lev-
els of FM symptoms (ﬁbromyalgianess score >10) at baseline, FM
development was studied in 9739 RA patients over a mean of
4.4 years. At the last observation, 7.4% of patients satisﬁed criteria,
although 19.8% satisﬁed criteria at some point during follow-up.
Overall, the study results indicate that multiple, inter-correlated
factors, including social disadvantage, psychological distress,
comorbidity, RA severity, HAQ, fatigue and FM variables predict
future development of FM. After diagnosis, patients move in both
directions across the diagnostic criteria cut points and thus the
authors introduce the concept of ‘‘ﬂuidity’’ of symptoms.
The report conﬁrms earlier ﬁndings that severe RA, worse out-
comes, comorbidity and socio-demographic disadvantage charac-
terize RA patients with FM [9]. A strength as well as a limitation
of the study is that diagnosis of FM was based on patient’s self-
reports. In an earlier study, the presence of FM in patients with
RA correlated with a higher Disease Activity Score (DAS28), but
not with objective RA activity, indicating that only the subjective
components of the DAS (including tender joints and self-reported
disease activity) were responsible for any differences in disease
activity [4]. This is in accordance with the ﬁnding that the percep-
tion and reporting of subjective measures, such as pain, can be
very different across populations and cultures, even after control-
ling for objective indicators of disease severity [5]. Using self-re-
ported pain and symptom severity as the only criteria for
‘‘selecting’’ FM patients thus complicates interpretation of the
present ﬁndings.
The results of this study also highlight the problem of contin-
uum versus discrete diagnosis of FM. This occurs because with
improvement or regression to the mean, or with ﬂares, patients
can move in and out of the diagnostic category. Like Schrödinger’s
cat, they spend half their future time criteria positive and half cri-
teria negative. As a result FM cannot be a diagnostic entity per se. It
follows that patients around the boundary point of diagnosis can-
not be accurately identiﬁed. A point on the continuum does not
warrant a deﬁnition of FM as a separate entity. It may even be
the reverse, namely that ‘‘there is no clinical basis by which FM
may be identiﬁed’’ [12].
A major question remains: is FM a separate entity at all?
Does satisfying FM criteria give us a reason to label someone0304-3959  2010 International Association for the Study of Pain. Published by Elsevie
doi:10.1016/j.pain.2010.11.020as a ﬁbromyalgia patient, FM thus becoming manifest in a ther-
apeutic domain [2,6]. A therapeutic domain is a real and heter-
ogeneous medical domain in which people, their thoughts and
practices, and medical technology in any form, coexist and com-
municate. In a therapeutic domain blood is aspirated, radio-
graphs are taken and classiﬁcation criteria are made and
applied. Within the domain a patient and therapist have initi-
ated a relationship, which is inﬂuenced by the media and polit-
ical pressure. This results in a looping effect where classiﬁcation
criteria and images give structure to perceptions and form the
description for human behavior; the person thus diagnosed (!)
constantly gradually conform into the classiﬁcation criteria,
which also have to be constantly revised. The ﬁbromyalgia ther-
apeutic domain would be one in which an individual manifests
with non-speciﬁc aches and pains, along with other features.
[2] Are we making at least some of the patients more ill by giv-
ing them the diagnosis? This has to my knowledge never been
proven, but is an impression of many clinicians. In my opinion,
there is no reason to use FM as a clinical construct for patients
with high levels of pain and fatigue.
The Oxford English dictionary deﬁnes genie as ‘‘a spirit of Ara-
bian folklore, traditionally depicted as imprisoned within a bottle
or lamp and capable of granting wishes when summoned’’. Hence
the title of this Commentary: Are we letting the genie out of the
bottle by allowing diagnosing of FM in RA?
The ACR diagnostic criteria for FM should not be seen as an
endorsement of the legitimacy and existence of ﬁbromyalgia as a
separate entity or diagnosis – the criteria are neutral on that point.
Existence and legitimacy is a concept that has existential, philo-
sophic, and social components, and is not resolved with the publi-
cation of these criteria. The issues that are worrisome about FM
remain. [8] With the new ACR criteria, it is now possible to study
widespread pain, FM and/or ﬁbromyalgianess, by using the WPI
and SS severity scales. In addition, in a paraphrase that recalls
Robert Lowell’s Santayana ascription, ‘‘There is no God and Mary
is His Mother’’, one can now study ﬁbromyalgia and ﬁbromyalgia-
ness without the requirement for belief in its existence [8]. FDA
approval of certain drugs for FM does not prove that such an entity
exists.
Does something comparable to FM exist in RA? I believe that
FM exists in patients, thanks to the fact that we doctors created
it; by diagnosing FM in chronic pain patients, RA may contribute
to the symptoms. Several papers have been written since the ﬁrst
report in 1983. These observations do not prove that such a phe-
nomenon exists, but only that many researchers thought that it
might exist. [1,3,4]. In fact, one of the problems we see in daily
practice is that doctors who diagnose – in fact classify – ﬁbromy-r B.V. Open access under the Elsevier OA license.
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‘‘FM patients’’ and sometimes forget to treat the underlying dis-
ease. And not surprisingly, Pharma is trying to increase ‘‘aware-
ness of FM’’ among doctors and general public, no doubt to
increase their sales [7].
What should we do? Should we keep the spirit (FM) imprisoned
within her bottle, or let it out so that it may grant wishes when
summoned by pharma or patient organizations? If FM is diagnosed
in RA patients, pharma will claim that the ‘disorder’ should be trea-
ted with anti-depressive drugs and painkillers, at the risk of forget-
ting to treat the underlying disease.
The diagnosis of FM in this study is based on self report. In the
near future people with widespread pain will search the Internet
and be able to diagnose themselves as ‘‘FM patients’’ by using
the WPI and SS severity scales. As Wolfe et al. state, this once again
raises the issue of the logical difﬁculty of predicting ﬁbromyalgia
when the predictor variable (Somatic Symptom count) is part of
the ﬁbromyalgia deﬁnition [11]. Is diagnosing FM perhaps the re-
sult of a circular argument?
The only real predictor of the incidence of FM is that the diag-
nosis is still being made: by labelling people and creating a thera-
peutic domain, in which patients behave like a FM patient, we may
create – at the same time – new FM patients. That is why I suggest
that we leave the FM genie in her bottle. If we change the thera-
peutic domain, perhaps ﬁbromyalgia will not become manifest in
an individual; indeed it may disappear. [2] In some respects, the
existence and persistence of FM is analogous to repetitive strain in-
jury (RSI), which disappeared in Australia within a year of its diag-
nosis no longer being recognized by legal authorities. [2] And some
ten years later in the Netherlands, the diagnosis of RSI almost dis-
appeared when patients were instead described as having chronic
non-speciﬁc neck and arm problems.Conﬂict of interest statement
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